The pharmaceutical sector continues to invest in its assists, as two separate merger and acquisition deals were announced this week reflecting continued consolidation and portfolio reshaping across the pharmaceutical industry.

GSK enters $690 million global licensing agreement with Alfasigma

GSK agreed to license linerixibat, its investigational treatment for cholestatic pruritus in primary biliary cholangitis (PBC), to Italian pharmaceutical company Alfasigma in a deal valued at upwards of $690 million.

PBC is a cholestatic liver disease in which disrupted bile flow leads to a buildup of bile acids thought to drive cholestatic pruritus, a debilitating internal itch that cannot be relieved by scratching.

The condition can cause sleep disturbance, fatigue, and significantly impaired quality of life. US data suggest that up to one-third of patients with clinically significant itch receive no treatment at all.¹

Under the terms of the agreement, Alfasigma is expected to acquire worldwide exclusive rights to develop, manufacture and commercialize linerixibat, while GSK will receive an upfront payment of $300 million, with a further $100 million due upon FDA approval, which is expected ahead of a PDUFA target date of March 24.¹

Additional milestones will be tied to regulatory approvals in the EU and UK, and up to $270 million in sales-based payments, round out the deal, alongside tiered double-digit royalties on global net sales.¹

Linerixibat is currently under regulatory review in the U.S., E.U., U.K., China and Canada, based on data from the Phase III Glisten trial, which met its primary and key secondary endpoints.¹ The drug carries Orphan Drug Designation in the U.S., E.U. and Japan.

For GSK, the deal represents a deliberate narrowing of focus. The company said the agreement allows it to concentrate on its next wave of liver disease innovation, including potential treatments for chronic hepatitis B, MASH and alcoholic liver disease.¹

"We're proud of the role GSK has played discovering and developing linerixibat to advance treatment in this rare disease with high unmet need," said Tony Wood, chief scientific officer at GSK. "This agreement sharpens GSK's focus to deliver our next wave of liver disease innovation."

Servier to acquire Day One Biopharmaceuticals in $2.5 billion deal

In other pharma M&A news, Servier agreed to acquire Day One Biopharmaceuticals in an all-cash transaction valued at approximately $2.5 billion, or $21.50 per share, in a deal expected to close in the second quarter of 2026.²

The acquisition is expected to add Day One's oncology pipeline to Servier's existing rare cancer portfolio, spanning programs from early stage through Phase III.² Day One's lead program targets pediatric low-grade glioma, a rare brain tumor that predominantly affects children.

For Servier, the deal advances its stated 2030 ambition to build out its position in rare oncology and targeted therapies. The French pharmaceutical group, which is governed by a foundation rather than shareholders, has framed the acquisition as a long-term scientific investment rather than a near-term commercial play.²

"This acquisition marks another decisive step in strengthening Servier's position in rare oncology," said Olivier Laureau, president of Servier. "We believe that combining our expertise will accelerate innovation for people living with a rare cancer."

Day One chief executive Jeremy Bender said Servier's track record in rare cancers made it a natural fit for the company's mission.

"Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low-grade glioma," Bender said. "Servier's dedication to the rare disease community preserves the patient-first mindset that has defined our company since the beginning."

Sources

1. GSK and Alfasigma announce agreement on worldwide rights for linerixibat GSK March 9, 2026 https://www.gsk.com/en-gb/media/press-releases/gsk-and-alfasigma-announce-agreement/
2. Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio Servier, Day One Pharmaceuticals March 6, 2026 https://www.prnewswire.com/news-releases/servier-and-day-one-biopharmaceuticals-announce-acquisition-to-expand-serviers-rare-oncology-portfolio-302706828.html